34937
document
Desogestrel and gestodene in oral contraceptives : 12 months ' assessment of carbohydrate and lipoprotein metabolism . We examined the influence on carbohydrate and lipoprotein metabolism of oral contraceptives ( OCs ) containing two new third-generation progestogens , desogestrel and gestodene . This was a prospective randomized study in which monophasic combinations of 20 micrograms ethinyl estradiol ( E2 ) and 150 micrograms desogestrel or 30 micrograms ethinyl E2 plus 75 micrograms gestodene were administered to 15 and 19 healthy women , respectively . An oral glucose tolerance test including measurement of insulin response was performed before treatment and after 3 , 6 , and 12 months of treatment . We also determined fasting plasma concentrations of total cholesterol ; high-density lipoprotein cholesterol , including the subfractions high-density lipoprotein2 cholesterol and high-density lipoprotein3 cholesterol ; low-density lipoprotein cholesterol ; very low-density lipoprotein cholesterol ; and triglycerides . A transient deterioration of glucose tolerance was observed despite unchanged levels of insulin after treatment with both compounds for 3 months . In both groups plasma levels of triglycerides , very low-density lipoprotein cholesterol , and high-density lipoprotein cholesterol increased significantly after 3 months . After 12 months , a significant increase in the high-density lipoprotein cholesterol/total cholesterol ratio was observed in the ethinyl E2-desogestrel group , and no persistent changes in low-density lipoprotein cholesterol could be demonstrated in any of the groups . Our results indicate that treatment with either compound for 12 months has no effect on carbohydrate or lipoprotein metabolism known to increase the risk of cardiovascular disease .
34938
Intervention_Pharmacological
oral contraceptives ( OCs )
34939
Intervention_Pharmacological
progestogens
34940
Intervention_Pharmacological
desogestrel
34941
Intervention_Pharmacological
gestodene
34942
Intervention_Pharmacological
ethinyl estradiol ( E2 )
34943
Intervention_Pharmacological
desogestrel
34944
Intervention_Pharmacological
ethinyl E2 plus 75 micrograms gestodene
34945
Outcome_Physical
carbohydrate and lipoprotein metabolism
34946
Outcome_Other
oral glucose tolerance test
34947
Outcome_Physical
fasting plasma concentrations of total cholesterol
34948
Outcome_Physical
high-density lipoprotein cholesterol
34949
Outcome_Physical
including the subfractions high-density lipoprotein2 cholesterol and high-density lipoprotein3 cholesterol
34950
Outcome_Physical
low-density lipoprotein cholesterol
34951
Outcome_Physical
very low-density lipoprotein cholesterol
34952
Outcome_Physical
triglycerides
34953
Outcome_Physical
transient deterioration of glucose tolerance
34954
Outcome_Physical
insulin
34955
Outcome_Physical
plasma levels of triglycerides
34956
Outcome_Physical
very low-density lipoprotein cholesterol
34957
Outcome_Physical
high-density lipoprotein cholesterol increased
34958
Outcome_Physical
high-density lipoprotein cholesterol/total cholesterol ratio
34959
Outcome_Physical
low-density lipoprotein cholesterol
34960
Outcome_Physical
carbohydrate or lipoprotein metabolism
34961
Participant_Condition
15 and 19 healthy women , respectively .